New cancer clinical trial: Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Published on: May 28, 2018 at 12:00PM
Condition:   Non-small Cell Lung Cancer
Intervention:   Drug: Telisotuzumab vedotin
Sponsor:   AbbVie
Not yet recruiting
https://ift.tt/2L64G3d